XOMA Royalty (XOMA) Non Operating Income (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Non Operating Income came in at $4.8 million in Q1 2026, up 5110.53% year-on-year from $91353.5 in Q1 2025, and up 580.0% quarter-over-quarter from $700000.0 in Q4 2025.
XOMA Royalty (XOMA) Non Operating Income (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Non Operating Income across 16 years of filings, most recently posting $4.8 million for Q1 2026.
- Non Operating Income for Q1 2026 came in at $4.8 million, up 5110.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.0 million (up 187.94% YoY), and the FY2025 annual result was $103000.0, down 98.51% from the prior year.
- Non Operating Income came in at $4.8 million for Q1 2026 at XOMA Royalty, up from $700000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $7.8 million in Q2 2025 to a low of -$215000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $557000.0 (2023), against an average of $1.3 million.
- Across the five-year window, Non Operating Income slumped 104.85% in 2025 and soared 5110.53% in 2026, its largest moves.
- XOMA Royalty's Non Operating Income stood at $219000.0 in 2022, then jumped by 79.91% to $394000.0 in 2023, then soared by 159.14% to $1.0 million in 2024, then sank by 31.44% to $700000.0 in 2025, then jumped by 580.0% to $4.8 million in 2026.
- The last three Non Operating Income figures came in at $4.8 million (Q1 2026), $700000.0 (Q4 2025), and $727000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 9.35 Mn |
| 10 | XOMA Royalty | 5.49 Mn | -60.59 Mn | - | 4.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.76 Mn |
| Dec 31, 2025 | 700,000.00 |
| Sep 30, 2025 | 727,000.00 |
| Jun 30, 2025 | 7.82 Mn |
| Mar 31, 2025 | -95,000.00 |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 2.05 Mn |
| Mar 31, 2024 | 1.96 Mn |
| Dec 31, 2023 | 394,000.00 |
| Sep 30, 2023 | 278,000.00 |
| Jun 30, 2023 | 557,000.00 |
| Mar 31, 2023 | 357,000.00 |
| Dec 31, 2022 | 219,000.00 |
| Sep 30, 2022 | 194,000.00 |
| Jun 30, 2022 | 97,000.00 |
| Mar 31, 2022 | -215,000.00 |
| Dec 31, 2021 | -430,000.00 |
| Sep 30, 2021 | -1.09 Mn |
| Jun 30, 2021 | 1.30 Mn |